Clinical Trials

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Location:

, Jacksonville, FL

Trial status:

Open for Enrollment

Why is this study being done?

PRIMARY OBJECTIVES: I. To determine the maximally tolerated dose (MTD) of the combination of ixabepilone and temsirolimus in patients with advanced solid tumors. II. To describe toxicity profiles associated with the combination of ixabepilone and temsirolimus. III. To assess preliminary efficacy of the combination of ixabepilone and temsirolimus. OUTLINE: This is a dose-escalation study. Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up for 3 months.

Last updated: 12/21/2012

NCT ID:

NCT01375829